Back to Top
Clinical Research
-
August 07, 2025
FDA Approval Spotlight: Linvoseltamab — A BCMA x CD3 Bispecific for Multiple Myeloma
In July 2025, the FDA granted accelerated approval to linvoseltamab, a BCMA × CD3 T-cell engaging bispecific antibody, for the treatment of ...
-
April 22, 2022
Introduction
In advancing cancer immunotherapy, antibodies against PD-1 have become a breakthrough and opened a new door for severely affected cancer patients. Nevertheless, the results of preclinical studies have faced various obstacles in transforming into successful clinical...
